Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors [1] [2].
In Vitro, The most extensively characterized aberration in fucosyltransferase (FUT) function in cancer is FUT8-mediated core fucosylation. FUT8 is frequently upregulated in human tumors. Depletion of FUT8 effectively blocks tumor growth and metastasis.
References:
[1]. Roider H, et al. BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapy[J]. Cancer Research, 2022, 82(12_Supplement): 2866-2866.
[2]. Roider HG, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin Exp Med. 2024;24(1):122. Published 2024 Jun 10.
In Vitro, The most extensively characterized aberration in fucosyltransferase (FUT) function in cancer is FUT8-mediated core fucosylation. FUT8 is frequently upregulated in human tumors. Depletion of FUT8 effectively blocks tumor growth and metastasis.
References:
[1]. Roider H, et al. BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapy[J]. Cancer Research, 2022, 82(12_Supplement): 2866-2866.
[2]. Roider HG, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin Exp Med. 2024;24(1):122. Published 2024 Jun 10.